Philip Tagari

Urinary Leukotriene E ₄ Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects

Pandora E. Christie, Philip Tagari, Anthony W. Ford‐Hutchinson et al. · American Review of Respiratory Disease · 1991 · 445 citations

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 426 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Active Cyclooxygenase-2 Inhibitor +10

Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530

Daniel Dubé, Marc Blouin, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 271 citations · Full text

Medicinal Chemistry, Aldehyde Dehydrogenase, Biochemistry +10

Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.

Melissa M. Carry, Victoria Korley, J T Willerson et al. · Circulation · 1992 · 172 citations · Full text

Morphological characterization of substance P‐like immunoreactive glomeruli in the superficial dorsal horn of the rat spinal cord and trigeminal subnucleus caudalis: A quantitative study

Alfredo Ribeiro‐da‐Silva, Philip Tagari, A. Claudio Cuello · The Journal of Comparative Neurology · 1989 · 136 citations